Skip to main content
SLS
NASDAQ Life Sciences

SELLAS Life Sciences Secures $42.6M from Warrant Exercises, Boosting Liquidity

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$5.5
Mkt Cap
$780.583M
52W Low
$0.952
52W High
$6.14
52W Position info
478% above low
Off High info
10% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

SLS has more than doubled off its 52-week low of $0.952.

Summary

SELLAS Life Sciences Group, Inc. announced it has received $42.6 million in proceeds from common stock warrant exercises since December 31, 2025, significantly enhancing its cash position.


Key Events · Financing and Capital Events · SLS

  • Significant Capital Infusion

    The company reported receiving a total of $42.6 million in proceeds from the exercise of common stock warrants since December 31, 2025.

  • Updated Proceeds from Warrant Exercises

    This includes an additional $16.1 million in proceeds from warrant exercises since January 8, 2026, building on the previously reported $26.5 million.

  • Shares Outstanding Update

    As of March 11, 2026, the company had 179,536,724 shares of common stock outstanding.


Analysis · SLS · Life Sciences

This 8-K reports a substantial capital infusion for SELLAS Life Sciences Group, Inc. The company has received a total of $42.6 million in proceeds from the exercise of common stock warrants since December 31, 2025, including an additional $16.1 million since January 8, 2026. This significant cash inflow strengthens the company's balance sheet and provides additional working capital, which is a positive development for its operational runway and financial stability. While warrant exercises lead to dilution, the capital raised is a critical benefit.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SLS was trading at $5.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $780.6M. The 52-week trading range was $0.95 to $6.14. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SLS - Latest Insights

SLS
Nov 18, 2026, 10:00 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $17.98
Real-time Price: $14.21 info
Change: -$3.77 (-21%) info
Market Cap: $2.785B info
SLS
Nov 18, 2026, 12:03 AM EST
Source: CNBC TV18
Importance Score:
7
Price at Filing: $17.14
Real-time Price: $14.21 info
Change: -$2.93 (-17%) info
Market Cap: $2.785B info
SLS
Nov 17, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $18.03
Real-time Price: $14.21 info
Change: -$3.82 (-21%) info
Market Cap: $2.785B info
SLS
Nov 17, 2026, 10:09 AM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $20.45
Real-time Price: $14.21 info
Change: -$6.24 (-31%) info
Market Cap: $2.785B info
SLS
Nov 17, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
10
Price at Filing: $8.00
Real-time Price: $14.21 info
Change: +$6.21 (+78%) info
Market Cap: $2.785B info